Recent advances in obesity pharmacotherapy

Current Clinical Pharmacology

Volumn 4, Issue 1, 2009, Pages 53-61

  Mayer, Marcos A ^a   Höcht, Christian ^a   Puyó, Ana ^a   Taira, Carlos A ^a  

^a UNIVERSIDAD DE BUENOS AIRES   (Argentina)

Author keywords

Anti obesity agents; Obesity; Orlistat; Pharmacotherapy; Rimonabant; Sibutramine

Indexed keywords

AMG 076; AMIODARONE; ANTICONVULSIVE AGENT; ANTIDIABETIC AGENT; ANTIOBESITY AGENT; ATOMOXETINE; CALCITRIOL; CETILISTAT; CLARITHROMYCIN; CYCLOSPORIN; EXENDIN 4; GSK 858464; KETOCONAZOLE; LEPTIN; METFORMIN; MONOAMINE OXIDASE INHIBITOR; NGD 4715; PLACEBO; PRAMLINTIDE; RIMONABANT; RITONAVIR; SEROTONIN AGONIST; SIBUTRAMINE; SULFONYLUREA; TARANABANT; TETRAHYDROLIPSTATIN; UNCLASSIFIED DRUG; UNINDEXED DRUG; VITAMIN; VITAMIN K GROUP; WARFARIN; CYCLOBUTANE DERIVATIVE; LACTONE; PIPERIDINE DERIVATIVE; PYRAZOLE DERIVATIVE;

ABDOMINAL OBESITY; ABDOMINAL PAIN; BLOOD PRESSURE; CALORIC INTAKE; CLINICAL TRIAL; CONSTIPATION; DEPRESSION; DIABETES MELLITUS; DIARRHEA; DIET THERAPY; DIZZINESS; DRUG ABSORPTION; DRUG ANTAGONISM; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CONTRAINDICATION; DRUG DESIGN; DRUG DOSE COMPARISON; DRUG EFFECT; DRUG EFFICACY; DRUG ELIMINATION; DRUG EXCRETION; DRUG HALF LIFE; DRUG INDUCED HEADACHE; DRUG MECHANISM; DRUG METABOLISM; DRUG POTENTIATION; DRUG SAFETY; DRUG SYNTHESIS; DRUG TARGETING; DRUG TOLERABILITY; DRUG WITHDRAWAL; ENERGY METABOLISM; FECES INCONTINENCE; FIRST PASS EFFECT; FLATULENCE; GASTROINTESTINAL TOXICITY; HEART RATE; HUMAN; HYPOGLYCEMIA; INSOMNIA; MOOD DISORDER; NAUSEA; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; PRIORITY JOURNAL; REVIEW; SIDE EFFECT; SINGLE DRUG DOSE; STEATORRHEA; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT; WEIGHT REDUCTION; XEROSTOMIA; ANIMAL; CARDIOVASCULAR DISEASE;

ANIMALS; ANTI-OBESITY AGENTS; CARDIOVASCULAR DISEASES; CYCLOBUTANES; HUMANS; LACTONES; OBESITY; PIPERIDINES; PYRAZOLES;

EID: 65549160462     PISSN: 15748847     EISSN: None     Source Type: Journal    
DOI: 10.2174/157488409787236128     Document Type: Review

References (97)

1. Haslam DW, James WPT. Obesity. Lancet 2005; 366: 1197-209.
2. Ogden CL, Carroll MD, Curtin LR, McDowell MA, Tabak CJ, Flegal KM. Prevalence of overweight and obesity in the United States, 1999-2004. JAMA 2006; 295: 1549-55.
3. Flegal KM, Graubard BI, Williamson DF, Gail MH. Cause-specific excess deaths associated with underweight, overweight, and obesity. JAMA 2007; 298: 2028-37.
4. Eckel RH. Nonsurgical management of obesity in adults. N Engl J Med 2008; 358: 1941-50.
5. Goldstein DJ. Beneficial effects of modest weight loss. Int J Obes Relat Metab Disord 1992; 16: 397-415.
6. Blackburn G. Effect of degree of weight loss on health benefits. Obes Res 1995; 3: 2112-15.
7. Colditz GA,Willett WC, Rotnitzky A, Manson JE. Weight gain as a risk factor for clinical diabetes mellitus in women. Ann Intern Med 1995; 122: 481-86.
8. Scheen AJ. The future of obesity: new drugs versus lifestyle interventions. Expert Opin Investig Drugs 2008; 17: 263-7.
9. The Practical Guide Identification, Evaluation, and Treatment of Overweight and Obesity in Adults. NIH Publication Number 00-4084. October 2000.
10. Hauptman JB, Jeunet FS, Hartmann D. Initial studies in humans with the novel gastrointestinal lipase inhibitor Ro 18-0467 (tetrahydrolipstatin). Am J Clin Nutr 1992; 55: 309-13.
11. Zhi J, Melia AT, Guerciolini R, Chung J, Kingberg J, Hauptman JR. Retrospective population-based analysis of the dose-response (fecal fat excretion) relationship of orlistat in normal and obese volunteers. Clin Pharmacol Ther 1994; 56: 82-85.
12. McNeely W, Benfield P. Orlistat. Drugs 1998; 56: 241-49.
13. Padwal RS, Majumdar SR. Drug treatments for obesity: orlistat, sibutramine, and rimonabant. Lancet 2007; 369: 71-77.
14. Filippatos TD, Derdemezis CS, Gazi IF, Nakou ES, Mikhailidis DP, Elisaf MS. Orlistat-associated adverse effects and drug interactions: a critical review. Drug Saf 2008; 31: 53-65.
15. Kiortsis DN, Filippatos TD, Elisaf MS. The effects of orlistat on metabolic parameters and other cardiovascular risk factors. Diabetes Metab 2005; 31: 15-22.
16. Fox M, Thumshirn M, Menne D, Stutz B, Fried M, Schwizer W. The pathophysiology of faecal spotting in obese subjects during treatment with orlistat. Aliment Pharmacol Ther 2004; 19: 311-21.
17. Torgerson JS, Hauptman J, Boldrin MN, Sjöström L. Xenical in the prevention of diabetes in obese subjects (XENDOS) study. A randomised study of orlistat as an adjunct to lifestyle for the prevention of type 2 diabetes in obese patients. Diabetes Care 2004; 27: 155-61.
18. MacWalter RS, Fraser HW, Armstrong KM. Orlistat enhances warfarin effect. Ann Pharmacother 2003; 37: 510-12.
19. Zhi J, Moore R, Kanitra L, Mulligan TE. Effects of orlistat, a lipase inhibitor, on the pharmacokinetics of three highly lipophilic drugs (amiodarone, fluoxetine and simvastatin) in healthy subjects. J Clin Pharmacol 2003; 43: 428-35.
20. Asberg A. Interactions between cyclosporine and lipid-lowering drugs: implications for organ transplant recipients. Drugs 2003; 63: 367-78.
21. Bigham S, McGuigan C, MacDonald BK. Reduced absorption of lipophilic anti-epileptic medications when used concomitantly with the anti-obesity drug orlistat letter. Epilepsia 2006; 47: 2207.
22. Miles JM, Leiter L, Hollander P, et al. Effect of orlistat in overweight and obese patients with type 2 diabetes treated with metformin. Diabetes Care 2002; 25: 1123-28.
23. Padwal R, Li SK, Lau DC. Long-term pharmacotherapy for obesity and overweight. Cochrane Database Syst Rev 2008; 3: CD004094.
24. Richelsen B, Tonstad S, Rossner S, et al. Effect of orlistat on weight regain and cardiovascular risk factors following a very-low-energy diet in abdominally obese patients. A 3-year randomized, placebo-controlled study. Diabetes Care 2007; 30: 27-32.
25. Zelber-Sagi S, Kessler A, Brazowsky E, et al. A double-blind randomized placebo-controlled trial of orlistat for the treatment of nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol 2006; 4: 639-44.
26. Jackson HC, Bearham MC, Hutchins LJ, Mazurkiewicz SE, Needham AM, Heal DJ. Investigation of the mechanisms underlying the hypophagic effects of the 5-HT and noradrenaline reuptake inhibitor, sibutramine, in the rat. Br J Pharmacol 1997; 121: 1613-18.
27. McNeely W, Goa KL. Sibutramine: a review of its contribution to the management of obesity. Drugs 1998; 56: 1093-124.
28. Finer N. Sibutramine: its mode of action and efficacy. Int J Obes Relat Metab Disord 2002; 26: 29-33.
29. Lean ME. How does sibutramine work? Int J Obes Relat Metab Disord 2001; 25: 8-11.
30. Luscombe GP, Hopcroft RH, Thomas PC, Buckett WR. The contribution of metabolites to the rapid and potent downregulation of rat cortical beta-adrenoceptors by the putative antidepressant sibutramine hydrochloride. Neuropharmacology 1989; 28: 129-34.
31. Florentin M, Liberopoulos EN, Elisaf MS. Sibutramine-associated adverse effects: a practical guide for its safe use. Obes Rev 2007 Epub ahead of print.
32. Jordan J, Scholze J, Matiba B, Wirth A, Hauner H, Sharma AM. Influence of Sibutramine on blood pressure: evidence from placebo-controlled trials. Int J Obes (Lond) 2005; 29: 509-16.
33. Kim SH, Lee YM, Jee SH, Nam CM. Effect of sibutramine on weight loss and blood pressure: a meta-analysis of controlled trials. Obes Res 2003; 11: 1116-23.
34. Von Haehling S, Lainscak M, Anker SD. Sibutramine in cardiovascular disease: is SCOUT the new STORM on the horizon? Eur Heart J 2007; 28: 2830-31.
35. Torp-Pedersen C, Caterson I, Coutinho W, et al. Cardiovascular responses to weight management and sibutramine in high-risk subjects: an analysis from the SCOUT trial. Eur Heart J 2007; 28, 2915-23.
36. James WP, Astrup A, Finer N, et al. Effect of sibutramine on weight maintenance after weight loss: a randomised trial. Lancet 2000; 356: 2119-25.
37. Rucker D, Padwal R, Li SK, Curioni C, Lau DCW. Long term pharmacotherapy for obesity and overweight: updated meta-analysis. BMJ 2007; 335: 1194-99.
38. Neovius M, Johansson K, Rossner S. Head-to-head studies evaluating efficacy of pharmaco-therapy for obesity: a systematic review and meta-analysis. Obes Rev 2008 [Epub ahead of print].
39. Di Marso V, Matias I. Endocannabinoid control of food intake and energy balance. Nat Neurosci 2005; 8: 585-89.
40. Van Gaal LF, Rissanen AM, Scheen AJ, Ziegler O, Rossner S. The RIO-Europe Study Group. Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1-year experience from the RIO-Europe study. Lancet 2005; 365: 1389-97.
41. Christensen R, Kristensen PK, Bartels EM, Bliddal H, Astrup A. Efficacy and safety of the weight-loss drug rimonabant: a meta-analysis of randomised trials. Lancet 2007; 17; 370: 1706-13.
42. Nissen SE, Nicholls SJ, Wolski K, et al. Effect of rimonabant on progression of atherosclerosis in patients with abdominal obesity and coronary artery disease: the STRADIVARIUS randomized controlled trial. JAMA 2008; 299: 1547-60.
43. Rumsfeld JS, Nallamothu BK. The hope and fear of rimonabant. JAMA 2008; 299: 1601-2.
44. Rimonabant Briefing Document: Endocrine and Metabolic Drugs Advisory Committee Meeting: NDA 21-888. US Food and Drug Administration Web site. -4306b1-fda-backgrounder.pdf. June 13, 2007. [Accessed May 23, 2008].
45. Van Gaal LF, Scheen AJ, Rissanen AM, et al. Long-term effect of CB1 blockade with rimonabant on cardiometabolic risk factors: 2-year results from the RIO-Europe Study. Eur Heart J 2008; 29 (14): 1761-71.
46. Pi-Sunyer FX, Aronne LJ, Heshmati HM, Devin J, Rosenstock J, RIO-North America Study Group. Effect of rimonabant, a cannabinoid-1 receptor blocker, on weight and cardiometabolic risk factors in overweight or obese patients. RIO-North America: a randomized controlled trial. JAMA 2006; 295: 761-75.
47. Després JP, Golay A, Sjostrom L. Rimonabant in obesity-lipids study group. effects on metabolic risk factors in overweight patients with dyslipidemia. N Engl J Med 2005; 353: 2121-34.
48. Scheen AJ. CB1 receptor blockade and its impact on cardiometabolic risk factors: overview of the RIO programme with rimonabant. J Neuroendocrinol 2008; 20: 139-46.
49. Scheen AJ, Finer N, Hollander P, Jensen MD, Van Gaal LF for the RIO-Diabetes Study Group. Efficacy and tolerability of rimonabant in overweight or obese patients with type 2 diabetes: a randomised controlled study. Lancet 2006; 368: 1660-72.
50. Ruilope LM, Després JP, Scheen A, et al. Effect of rimonabant on blood pressure in overweight/obese patients with/without comorbidities: analysis of pooled Rimonabant In Obesity (RIO) study results. J Hypertens 2008; 26: 357-67.
51. Grassi G, Quarti-Trevano F, Seravalle G, Arenare F, Brambilla G, Mancia G. Blood pressure lowering effects of rimonabant in obesity-related hypertension. J Neuroendocrinol 2008; 20: 63-8.
52. Rosenstock J, Iranmanesh A, Hollander PA. Improved glycemic control with weight loss plus beneficial effects on atherogenic dyslipidemia with rimonabant in drug-naive type 2 diabetes: the SERENADE trial (Abstract). Diabetes 2007; 56: A49-A50.
53. Fong TM, Guan XM, Marsh DJ, et al. Anti-obesity efficacy of a novel cannabinoid-1 receptor inverse agonist MK-0364 in rodents. J Pharmacol Exp Ther 2007; 321: 1013-1022.
54. Addy C, Li S, Agrawal N, et al. Safety, tolerability, pharmacokinetics, and pharmacodynamic properties of taranabant, a novel selective cannabinoid-1 receptor inverse agonist, for the treatment of obesity: results from a double-blind, placebo-controlled, single oral dose study in healthy volunteers. J Clin Pharmacol 2008; 48: 418-27.
55. Hofbauer KG, Nicholson JR, Boss O. The Obesity Epidemic: Current and Future Pharmacological Treatments. Annu Rev Pharmacol Toxicol 2007; 47: 565-92.
56. Thomsen WJ, Grottick AJ, Menzaghi F, et al. Lorcaserin, a novel selective human 5-hydroxytryptamine2C agonist: in vitro and in vivo pharmacological characterization. J Pharmacol Exp Ther 2008; 325: 577-87.
57. Smith BM, Smith JM, Tsai JH, et al. Discovery and structure-activity relationship of (1R)-8-chloro-2,3,4,5-tetrahydro-1-methyl-1H-3-benzazepine (Lorcaserin), a selective serotonin 5-HT2C receptor agonist for the treatment of obesity. J Med Chem 2008; 51: 305-13.
58. Gadde KM, Yonish GM, Wagner HR 2nd, et al. Atomoxetine for weight reduction in obese women: a preliminary randomised controlled trial. Int J Obes 2006; 30: 1138-42.
59. ALS CNTF Treatment Study Group. A double-blind placebo-controlled clinical trial of subcutaneous recombinant human ciliary neurotrophic factor (rHCNTF) in amyotrophic lateral sclerosis. Neurology 1996; 46: 1244-9.
60. Gloaguen I, Costa P, Demartis A, et al. Ciliary neurotrophic factor corrects obesity and diabetes associated with leptin deficiency and resistance. Proc Natl Acad Sci USA 1997; 94: 6456-61.
61. Matthews VB, Febbraio MA. CNTF: a target therapeutic for obesity-related metabolic disease? J Mol Med 2008; 86: 353-61.
62. Ettinger MP, Littlejohn TW, Schwartz SL, et al. Recombinant variant of ciliary neurotrophic factor for weight loss in obese adults: a randomized, dose-ranging study. JAMA 2003; 289: 1826-32.
63. Padwal R. Cetilistat, a new lipase inhibitor for the treatment of obesity. Curr Opin Investig Drugs 2008; 9: 414-21.
64. Kopelman P, Bryson A, Hickling R, et al. Cetilistat (ATL-962), a novel lipase inhibitor: a 12-week randomized, placebo-controlled study of weight reduction in obese patients. Int J Obes (Lond) 2007; 31: 494-99.
65. Cefalu WT. Pharmacotherapy for the treatment of patients with type 2 diabetes mellitus: rationale and specific agents. Clin Pharmacol Ther 2007; 81: 636-49.
66. Smith SR, Blundell JE, Burns C, et al. Pramlintide treatment reduces 24-h caloric intake and meal sizes and improves control of eating in obese subjects: a 6-wk translational research study. Am J Physiol Endocrinol Metab 2007; 293: 620-27.
67. Mafong DD, Henry RR. Exenatide as a treatment for diabetes and obesity: implications for cardiovascular risk reduction. Curr Atheroscler Rep 2008; 10: 55-60.
68. Viswanathan P, Chaudhuri A, Bhatia R, Al-Atrash F, Mohanty P, Dandona P. Exenatide therapy in obese patients with type 2 diabetes mellitus treated with insulin. Endocr Pract 2007; 13: 444-50.
69. Kowalski TJ, Sasikumar T. Melanin-concentrating hormone receptor-1 antagonists as antiobesity therapeutics current status. Biodrugs 2007; 21: 311-21.
70. Ahnaou A, Drinkenburg WH, Bouwknecht JA, Alcazar J, Steckler T, Dautzenberg FM. Blocking melanin-concentrating hormone MCH1 receptor affects rat sleep-wake architecture. Eur J Pharmacol 2008; 579: 177-88.
71. Heymsfield SB, Greenberg AS, Fujioka K, et al. Recombinant leptin for weight loss in obese and lean adults: a randomized, controlled, dose-escalation trial. JAMA 1999; 282: 1568-75.
72. Vincent RP, le Roux CW. New agents in development for the management of obesity. Int J Clin Pract 2007; 61: 2103-12.
73. Hallschmid M, Benedict C, Schultes B, et al. Towards the therapeutic use of intranasal neuropeptide administration in metabolic and cognitive disorders. Regul Pept 2008 Mar 25. [Epub ahead of print].
74. Kastin AJ, Pan W. Intranasal leptin: blood-brain barrier bypass (BBBB) for obesity? Endocrinology 2006; 147: 2086-87.
75. Fliedner S, Schulz C, Lehnert H. Brain uptake of intranasally applied radioiodinated leptin in Wistar rats. Endocrinology 2006; 147: 2088-94.
76. Herzog H. Neuropeptide Y and energy homeostasis: insights from Y receptor knockout models. Eur J Pharmacol 2003; 480: 21-29
77. Ste Marie L, Luquet S, Cole TB, Palmiter RD. Modulation of neuropeptide Y expression in adult mice does not affect feeding. Proc Natl Acad Sci USA 2005; 102: 18632-37.
78. Erondu N, Addy C, Lu K, et al. NPY5R antagonism does not augment the weight loss efficacy of orlistat or sibutramine. Obesity (Silver Spring) 2007; 15: 2027-42.
79. MacNeil DJ. NPY Y1 and Y5 receptor selective antagonists as anti-obesity drugs. Curr Top Med Chem 2007; 7: 1721-33.
80. Cone RD. Anatomy and regulation of the central melanocortin system. Nat Neurosci 2005; 8: 571-78.
81. O'Rahilly S, Yeo GS, Farooqi IS. Melanocortin receptors weigh in. Nat Med 2004; 10: 351-52.
82. Kuo JJ, Silva AA, Hall JE. Hypothalamic melanocortin receptors and chronic regulation of arterial pressure and renal function. Hypertension 2003; 41: 768-74.
83. Nordheim U, Nicholson JR, Dokladny K, Dunant P, Hofbauer KG. Cardiovascular responses to melanocortin 4-receptor stimulation in conscious unrestrained normotensive rats. Peptides 2006; 27: 438-43.
84. Wessells H, Blevins JE, Vanderah TW. Melanocortinergic control of penile erection. Peptides 2005; 26: 1972-77.
85. Yanagisawa T, Sato T, Yamada H, Sukegawa J, Nunoki K. Selectivity and potency of agonists for the three subtypes of cloned human beta-adrenoceptors expressed in Chinese hamster ovary cells. Tohoku J Exp Med 2000; 192: 181-93.
86. Collins S, Cao W, Robidoux J. Learning new tricks from old dogs: betaadrenergic receptors teach new lessons on firing up adipose tissue metabolism. Mol Endocrinol 2004; 18: 2123-31.
87. Cohen P, Friedman JM. Leptin and the control of metabolism: role for stearoyl-CoA desaturase-1 (SCD-1). J Nutr 2004; 134: 2455-63.
88. Chen HC, Farese RVJ. Inhibition of triglyceride synthesis as a treatment strategy for obesity. Lessons from DGAT1-deficient mice. Arterioscler Thromb Vasc Biol 2005; 25: 482-86.
89. Zhao G, Souers AJ, Voorbach M, et al. Validation of diacyl glycerolacyltransferase i as a novel target for the treatment of obesity and dyslipidemia using a potent and selective small molecule inhibitor. J Med Chem 2008; 51: 380-83.
90. Heffernan M, Summers RJ, Thorburn A, et al. The effects of human GH and its lipolytic fragment (AOD 9604) on lipid metabolism following chronic treatment in obese mice and beta(3)-AR knock-out mice. Endocrinology 2001; 142: 5182-89.
91. Sanchis D, Balada F, del Mar Grasa M, et al. Oleoyl-estrone induces the loss of body fat in rats. Int J Obes 1996; 20: 588-94.
92. del Mar Grasa M, Cabot C, Esteve M, et al. Daily oral oleoylestrone gavage induces a dose-dependent loss of fat in Wistar rats. Obes Res 2001; 9: 202-09.
93. Esteve M, Savall P, Virgilli J, Fernández-López JA, Remesar X, Alemany M. Modulation by leptin, insulin and corticosterone of oleoylestrone synthesis in cultured 3T3L1 cells. Biosci Rep 2001; 21: 755-63.
94. Fernández-Real JM, Sanchis D, Ricart W, et al. Plasma oestrone-fatty acid ester levels are correlated with body fat mass in humans. Clin Endocrinol 1999; 50: 253-60.
95. Cabot C, Masanés R, Bulló M, et al. Plasma acyl-estrone levels are altered in obese women. Endocr Res 2000; 26: 465-76.
96. Salas A, Noé V, Ciudad CJ, Mar Romero M, Remesar X, Esteve M. Short-term oleoyl-estrone treatment affects capacity to manage lipids in rat adipose tissue. BMC Genomics 2007; 8: 292.
97. Spalding KL, Arner E, Westermark PO, et al. Dynamics of fat cell turnover in humans. Nature 2008; 453: 783-7.